Overview
- CVS reported adjusted second-quarter earnings of $2.58 per share, well above analysts’ estimate, and net income of about $2.9 billion.
- Quarterly revenue rose to roughly $106.1 billion, reflecting higher pharmacy volumes and PBM sales tied to drug mix and brand inflation.
- The company raised full-year adjusted EPS guidance to $7.90–$8.10 as Aetna’s medical loss ratio improved to 87.4% and high Star ratings delivered government bonus payments.
- CVS said health services operating profit climbed 10% to $1.73 billion while it plans to close 16 underperforming Oak Street primary-care sites and expand MinuteClinic access to weight-loss drug visits for $29.
- Leadership warned that elevated medical costs, regulatory and reimbursement pressures, and macroeconomic risks remain and could limit future margin gains even as the company monetizes GLP-1 demand and restores insurer margins.